111 results
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
14 May 24
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:10pm
cord stimulation program), business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
26 Mar 24
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
9:20am
strategy, market size, potential growth opportunities, and future operations. Although NeuroOne believes that we have a reasonable basis for each forward
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
15 Mar 24
Submission of Matters to a Vote of Security Holders
4:30pm
payments, clinical and pre - clinical testing, what the future may hold for electrical stimulation and NeuroOne's potential role, business strategy, market … (510k) clearance for OneRF Ablation system in December 2023; for use with EVO sEEG ® electrodes to treat neurologic conditions Strategy to access
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
13 Feb 24
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:15pm
capabilities of our OneRF Ablation System, SCS and drug delivery programs, business strategy, market size, potential growth opportunities, future
8-K
EX-99.1
akywo9 nbnjitroq
14 Dec 23
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-99.1
9muay84y26 hfi8k
11 Dec 23
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
8:15am
8-K
EX-99.1
mm29o4m1ysmir2 hy1fx
16 Nov 23
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
8:00am
8-K
EX-99.1
6h2a979x
14 Nov 23
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
5:28pm
8-K
EX-99.1
w3p3hvqgjb06mgq
7 Nov 23
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
8:15am
8-K
EX-99.1
6h2miiuq nt3qia
14 Aug 23
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:15pm
424B5
xf921l1nn3a 9l1
26 Jul 23
Prospectus supplement for primary offering
4:24pm
424B5
yb2k48sme5uhgf
24 Jul 23
Prospectus supplement for primary offering
4:43pm
8-K
EX-99.1
v4gy5 mdxxwkw
11 May 23
NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
e9ixijm
22 Dec 22
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results
9:11am